Strategic report Directors report Risk review and capital review FINANCIAL STATEMENTS Supplementary information Company balance sheet As at 31 December 2017 2017 2016 Notes $million $million Non-current assets Investments in subsidiary undertakings 32 34,853 33,853 Current assets Derivative financial instruments 36, 39 70 529 Investment securities 39 12,159 15,009 Amounts owed by subsidiary undertakings 39 15,714 15,230 Taxation 3 27,946 30,768 Current liabilities Derivative financial instruments 39 492 1,541 Other creditors 405 399 Taxation 14 897 1,954 Net current assets 27,049 28,814 Total assets less current liabilities 61,902 62,667 Noncurrent liabilities Debt securities in issue 39 16,169 17,132 Subordinated liabilities and other borrowed funds 27, 39 13,882 14,582 30,051 31,714 Total assets less liabilities 31,851 30,953 Equity Share capital and share premium account 28 7,097 7,091 Other reserves 17,129 17,129 Retained earnings 2,664 2,764 Total shareholders equity 26,890 26,984 Other equity instruments 28 4,961 3,969 Total equity 31,851 30,953 The Company has taken advantage of the exemption in section 408 of the Companies Act 2006 not to present its individual statement of comprehensive income and related notes that form a part of these financial statements.
The Company pro t for the year after tax is $210 million 2016: $189 million.
The notes on pages 208 to 307 form an integral part of these financial statements.
These financial statements were approved by the Board of directors and authorised for issue on 27 February 2018 and signed on its behalf by: Jos Vials Bill Winters Andy Halford Group Chairman Group Chief Executive Group Chief Financial Of cer 205
